Samples and Logistics Clause Samples
The "Samples and Logistics" clause defines the responsibilities and procedures related to the provision, handling, and transportation of product samples between parties. It typically outlines who is responsible for supplying samples, the conditions under which they are delivered, and the logistics involved, such as shipping methods, costs, and timelines. By clearly allocating duties and expectations regarding samples, this clause helps prevent misunderstandings and ensures smooth coordination in the exchange and evaluation of sample products.
Samples and Logistics. Biocept will be responsible for the logistics associated with its own marketing efforts and performance of the Technical Component of the Assay, including distribution of shipping materials and sample collection systems by its sales representatives, patient referral and customer service.
Samples and Logistics. (i) Life Technologies will be responsible for the logistics associated with its marketing efforts and performance of the Professional Components of the Tests; provided, however, that Biocept will send the sample collection systems directly to customers identified by Life Technologies who order the Test, at Life Technologies’ expense. Biocept will further work with Life Technologies to facilitate transport of collected samples from the customer to Biocept’s CLIA laboratory. Life Technologies will work collaboratively with Biocept on patient referral, billing and collections in accordance with Section 3.5(c)(iii), reporting of results and reporting quality control, and insurance or patient reimbursement.
Samples and Logistics. (i) Clarient will be responsible for the logistics associated with its own marketing efforts and performance of Professional Components of the Diagnostic Tests, including distribution of sample shipping kits, sample transport to Biocept, patient referral, billing and collections in accordance with Section 3.5(b)(iii), reporting of results and reporting quality control, and insurance or patient reimbursement.
(ii) Clarient will, at its discretion and to the extent it is able, provide clinical samples to Biocept for the development and validation of the Diagnostic Tests at no cost, and will, at its discretion, test, for comparative purposes in research and validation studies only and not for provision of the results to patients, reasonable numbers of such clinical samples, and samples sourced by Biocept, using the CellSearch technology, at cost plus ten percent (10%).